Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaratumab + Doxorubicin in Advanced Soft Tissue Sarcoma
NCT01185964Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2010
- Primary completion
- Aug 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of olaratumab in soft tissue sarcoma (STS), sponsored by Eli Lilly and Company. Started Oct 2010; status: completed.
02
Drugs
olaratumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT01185964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01185964.